Alcon to build Singapore plant

Article

As the Asian eyecare market begins to explode, Alcon is preparing to be close to the action by adding a manufacturing plant in Singapore.

As the Asian eyecare market begins to explode, Alcon is preparing to be close to the action by adding a manufacturing plant in Singapore.

The 250,000-square-foot plant, which will employ 150 people, will manufacture pharmaceuticals to be distributed throughout Asia, with the exception of Japan.

Today, that region is supplied from plants in Fort Worth, US and Purrs, Belgium, said Doug MacHatton, Alcon's vice president of investor relations and corporate communications. Alcon has a third plant in Barcelona, Spain.

MacHatton said the region has experienced compound annual growth topping 20% in recent years. Having a plant in the area will help deliver pharmaceuticals more quickly and demonstrate the company's commitment to serving the Asian market, he said.

"I think it's not only the cost (you save), it's the time and revenue that you're investing in a local area - that enhances your ability to gain contractual revenue," MacHatton said.

"It's an opportunity to invest in an area of tremendous growth," he added, noting that the company has witnessed growth in India, Viet Nam, and other parts of south-east Asia. "We've already experienced growth and Singapore's an excellent location."

Alcon plans to break ground at the Tuas Biomedical Park in 2009 with the plant fully operational by 2012. The company expects to produce 53 million units per year by the third year of operation, compared with 125 million units per year from the Fort Worth plant and 110 units per year from the Puurs plant. Both of those sites employ about 250 people, according to Kat Golden, Alcon's manager, corporate communications.

"We do not expect to see a large increase in the site's overall employee headcount because efficiencies will come from our putting in place today management, quality assurance and engineering employees," she said.

Singapore's skilled workforce and stable government and utility infrastructure make it a logical place in which to build a base for growth, MacHatton said.

"Given the rapid growth in this region, this plant is integral to our ability to meet future market demands," Ed McGough, Alcon's senior vice president, global manufacturing and technical operations, said in a prepared statement.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.